key: cord-0275699-ll2z7cee authors: Bailey, M.; Spick, M. P.; Longman, K.; Frampas, C.; Lewis, H. M.; Costa, C. D.; Stewart, A.; Dunn-Walters, D.; Skene, D.; Greener, D.; Evetts, G. E.; Trivedi, D. K.; Barran, P.; Pitt, A.; Hollywood, K. title: Untargeted saliva metabolomics reveals COVID-19 severity: Saliva Metabolomics for SARS-COV-2 Prognosis date: 2021-07-07 journal: nan DOI: 10.1101/2021.07.06.21260080 sha: 519025d3c0727db541376177248a6674d3f65586 doc_id: 275699 cord_uid: ll2z7cee ABSTRACT Background The COVID-19 pandemic is likely to represent an ongoing global health issue given the potential for vaccine escape and the low likelihood of eliminating all reservoirs of the disease. Whilst diagnostic testing has progressed at pace, there is an unmet clinical need to develop tests that are prognostic, to triage the high volumes of patients arriving in hospital settings. Recent research has shown that serum metabolomics has potential for prognosis of disease progression. 1 In a hospital setting, collection of saliva samples is more convenient for both staff and patients, and therefore offers an alternative sampling matrix to serum. We demonstrate here for the first time that saliva metabolomics can reveal COVID-19 severity. Methods 88 saliva samples were collected from hospitalised patients with clinical suspicion of COVID-19, alongside clinical metadata. COVID-19 diagnosis was confirmed using RT-PCR testing. COVID severity was classified using clinical descriptors first proposed by SR Knight et al. Metabolites were extracted from saliva samples and analysed using liquid chromatography mass spectrometry. Results In this work, positive percent agreement of 1.00 between a PLS-DA metabolomics model and the clinical diagnosis of COVID severity was achieved. The negative percent agreement with the clinical severity diagnosis was also 1.00, for overall percent agreement of 1.00. Conclusions This research demonstrates that liquid chromatography-mass spectrometry can identify salivary biomarkers capable of separating high severity COVID-19 patients from low severity COVID-19 patients in a small cohort study. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint 2 This research demonstrates that liquid chromatography-mass spectrometry can 48 identify salivary biomarkers capable of separating high severity COVID-19 patients 49 from low severity COVID-19 patients in a small cohort study. 50 51 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint The SARS-CoV-2 pandemic has caused a sustained threat to global health since the 53 discovery of the virus in 2019. 2 Whilst great strides have been made in both treatment 54 and vaccination development, 3,4 the disease has inflicted multiple waves of infection 55 throughout the world during 2020 and into 2021. 5,6 COVID-19 has higher fatality rates 56 than seasonal influenza, 7 and in addition, new variants are constantly evolving with 57 the potential for either reduced vaccine effectiveness or altered lethality. 8 As a 58 consequence, there is a continuing need both for better understanding of the impact 59 of COVID-19 on the host metabolism as well as for prognostic tests that can be used 60 to triage the high volumes of patients arriving in hospital settings. 61 Nasopharyngeal swabs followed by polymerase chain reaction (PCR) have been 62 adopted worldwide for SARS-CoV-2 detection. However, supply chains for swabs 63 rapidly collapsed amongst exponential increases in demand for testing, highlighting 64 the urgency for alternative sample types and testing approaches. Furthermore, whilst 65 PCR tests are easily deployable and highly selective for the virus, these approaches 66 yield no prognostic information and cannot easily be delivered for rapid turnaround at 67 the point of care, for example during a hospital admissions process. In contrast, tests 68 based on mass spectrometry can be provided in minutes, with mass spectrometry 69 instrumentation typically available in hospital pathology laboratories. Prognostic tests, 70 whilst challenging due to the varied phenotypes that may present themselves, 9 could 71 be used to manage demand for hospitalisation and treatment, especially should 72 vaccine escape lead to future waves of COVID-19 infection. Metabolic biomarkers in serum have been identified that carry prognostic information, 74 10,11 but sampling blood is invasive. Our experience in collecting and analysing patient 75 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint had the capacity to consent to the study, and were asked to sign an Informed Consent 100 Form; those that did not have this capacity or who did not sign the form were not 101 sampled. Consenting participants were categorised by the hospital as either "query The range in time between symptom onset and saliva sampling ranged from 1 day to 115 > 1 month, an inevitable consequence of collecting samples in a pandemic situation. Each participant provided a sample of saliva by spitting directly into a falcon tube which 117 was placed on ice immediately after collection. Samples were transferred on ice from 118 the hospital to the University of Surrey by courier within 4 hours of collection, to 119 minimise changes to salivary metabolites. 21 Once received at University of Surrey, 120 the samples were stored at minus 80 °C until analysis. Alongside saliva collection, metadata for all participants was also collected covering 122 inter alia sex, age, comorbidities (based on whether the participant was receiving 123 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint instrumental and extraction variation (n=7 and 3 respectively), and 10 participant 149 samples, randomised for positive/negative, with 3 repeat analyses for each. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. In this study all participants were recruited in a hospital setting with at least potential is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. Initially separation of COVID-19 positive versus negative participants was tested, as 254 well as separation of COVID-19 high severity and low severity. As shown in Figure 1A , CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. Figure 1B shows separation for COVID-19 high severity participants versus low 262 severity participants. The optimal separation was found using 5 components. Using The normalised prognostic dataset was also processed for pathway analysis to 291 explore changes in metabolic pathways relating to COVID-19 ( Figure S6) High Low . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint Whilst no fully independent prognostic validation set was available, it was decided to 298 project the PLS-DA model obtained for high severity versus low severity participants 299 on to COVID-19 negative participants. Given that these participants should not show 300 features associated with high severity COVID-19, this was considered to offer 301 additional information. The confusion matrix for the results of the projection is shown 302 in Table 2 below. In this study, saliva samples were provided under conditions that could be practically 317 achieved in a hospital pandemic setting, albeit this meant no scope for abstinence 318 from food and / or drink before saliva sampling, and no prior rinsing of the mouth, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. be noted, however, that the correlation of metabolites between saliva and blood has 340 previously been found to be weak or in some cases non-existent, 31,32 and the same 341 may be true for the saliva and blood of individuals testing positive for COVID-19. Direct 342 analysis of paired blood samples would be required to draw any definitive conclusion 343 on differential dysregulation of metabolites between serum and saliva. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint In this work a number of features have been identified for the first time that may 346 differentiate the saliva of those presenting with high severity and low severity COVID-347 19. We believe that saliva has potential to add to understanding of the progression 348 and severity of COVID-19. In addition, saliva may be collected less invasively than 349 other biofluids, and mass spectrometry techniques have the advantage of being often CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2021. Metabolomic analyses of 26 Coronavirus in Saliva Saliva NMR-Based Metabolomics 447 in the War Against Saliva as a gold-standard 449 sample for SARS-CoV-2 detection The Functions of Saliva Capillary 453 electrophoresis mass spectrometry-based saliva metabolomics identified oral, 454 breast and pancreatic cancer-specific profiles Using an Untargeted Metabolomics 456 Approach to Identify Salivary Metabolites in Women with Breast Cancer Existing Drugs 459 Considered as Promising in COVID-19 Therapy The COVID-19 MS Coalition-461 accelerating diagnostics, prognostics, and treatment Changes to the sebum lipidome upon 464 COVID-19 infection observed via rapid sampling from the skin International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted Nearest neighbor imputation algorithms: A critical 472 evaluation Normalization of peak intensities 475 in bottom-up MS-based proteomics using singular value decomposition NOREVA: Normalization and evaluation of MS-478 based metabolomics data R: A Language and Environment for Statistical Computing Using MetaboAnalyst 4.0 for Comprehensive and 482 Paper microfluidic device using 484 carbon dots to detect glucose and lactate in saliva samples COVID-19 infection alters kynurenine 487 and fatty acid metabolism, correlating with IL-6 levels and renal status CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.06.21260080 doi: medRxiv preprint